Terms: = Prostate cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Staging
64 results:
1. The Ability of the STAR-cap staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
2. Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative.
Chandrasekar T; Denisenko A; Mico V; McPartland C; Shah Y; Mark JR; Lallas CD; Fonshell C; Danella J; Jacobs B; Lanchoney T; Raman JD; Tomaszewski J; Reese A; Singer EA; Ginzburg S; Smaldone M; Uzzo R; Guzzo TJ; Trabulsi EJ
Urol Oncol; 2023 Aug; 41(8):355.e1-355.e8. PubMed ID: 37357123
[TBL] [Abstract] [Full Text] [Related]
3. Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
Diamand R; Peltier A; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; Nguyen TA; Fournier G; Fiard G; Ploussard G; Roumeguère T; Albisinni S
Prostate; 2023 May; 83(6):572-579. PubMed ID: 36705314
[TBL] [Abstract] [Full Text] [Related]
4. Free-indocyanine green-guided pelvic lymph node dissection during radical prostatectomy.
Claps F; de Pablos-Rodríguez P; Gómez-Ferrer Á; Mascarós JM; Marenco J; Collado Serra A; Casanova Ramón-Borja J; Calatrava Fons A; Trombetta C; Rubio-Briones J; Ramírez-Backhaus M
Urol Oncol; 2022 Nov; 40(11):489.e19-489.e26. PubMed ID: 36175317
[TBL] [Abstract] [Full Text] [Related]
5. Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative.
Mora S; Qi J; Morgan TM; Brede CM; Peabody J; George A; Lane BR
Urol Oncol; 2022 Aug; 40(8):380.e1-380.e9. PubMed ID: 35778348
[TBL] [Abstract] [Full Text] [Related]
6. Calibrated Regression Models Based on the Risk of Clinical Nodal Metastasis Should be Used as Decision Aids for prostate cancer staging to Reduce Unnecessary Imaging.
Hayes M; Yu Y; Bassale S; Chakiryan N; Chen Y; Ye S; Garzotto M; Kopp R
Clin Genitourin Cancer; 2022 Dec; 20(6):e490-e497. PubMed ID: 35649886
[TBL] [Abstract] [Full Text] [Related]
7. Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes.
Qaoud Y; Herrera-Caceres JO; Bass R; Berjaoui MB; Tiwari R; Kenk M; Lajkosz K; Finelli A; Perlis N; Klotz L; Fleshner N
Urol Oncol; 2022 Jul; 40(7):343.e1-343.e6. PubMed ID: 35537905
[TBL] [Abstract] [Full Text] [Related]
8. Performance of a prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk prostate cancer.
Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
[TBL] [Abstract] [Full Text] [Related]
9. Risk Stratification of Patients Candidate to Radical prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups.
Mazzone E; Gandaglia G; Ploussard G; Marra G; Valerio M; Campi R; Mari A; Minervini A; Serni S; Moschini M; Marquis A; Beauval JB; van den Bergh R; Rahota RG; Soeterik T; Roumiguiè M; Afferi L; Zhuang J; Guo H; Mattei A; Gontero P; Cucchiara V; Stabile A; Fossati N; Montorsi F; Briganti A
Eur Urol; 2022 Feb; 81(2):193-203. PubMed ID: 34399996
[TBL] [Abstract] [Full Text] [Related]
10. Validation of the STAR-cap Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and cancer-specific Mortality After Radical prostatectomy in a European Cohort.
Würnschimmel C; Pose RM; Wenzel M; Tian Z; Incesu RB; Karakiewicz P; Graefen M; Tilki D
Eur Urol; 2021 Oct; 80(4):400-404. PubMed ID: 34162491
[TBL] [Abstract] [Full Text] [Related]
11. Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study.
Tosco L; Devos G; Schillebeeckx L; Pans S; Goffin K; Everaerts W; Van Poppel H; Joniau S
Urol Oncol; 2022 Jan; 40(1):7.e9-7.e17. PubMed ID: 34099385
[TBL] [Abstract] [Full Text] [Related]
12. Validation of the new STAR-cap prognostic group staging system in prostate cancer patients treated with radiation therapy.
Dariane C; Taussky D; Delouya G; Wenzel M; Karakiewicz P; Saad F; Würnschimmel C
World J Urol; 2021 Nov; 39(11):4127-4133. PubMed ID: 34052878
[TBL] [Abstract] [Full Text] [Related]
13. Multiparametric MRI with in-bore targeted biopsy in the diagnostic pathway of prostate cancer: Data from a single institution experience.
Nawfal G; Sarkis J; Assaf S; Mjaess G; Abi Chebel J; Semaan A; Alkassis M; Nemr E; Kamel G; Ayoub N; Sarkis P
Urol Oncol; 2021 Nov; 39(11):781.e9-781.e15. PubMed ID: 33676850
[TBL] [Abstract] [Full Text] [Related]
14. hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review.
Morozov A; Potoldykova N; Chinenov D; Enikeev M; Glukhov A; Shpikina A; Goryacheva E; Taratkin M; Malavaud B; Enikeev D
Urol Oncol; 2021 Aug; 39(8):498.e21-498.e33. PubMed ID: 33676848
[TBL] [Abstract] [Full Text] [Related]
15. Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?
Grant Owens R; Loloi J; Lehman EB; Kaag MG; Raman JD; Merrill SB
Urol Oncol; 2021 Jul; 39(7):433.e9-433.e15. PubMed ID: 33610444
[TBL] [Abstract] [Full Text] [Related]
16. Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy.
Prabhu N; Kapur N; Catalona W; Leikin R; Helenowski I; Jovanovich B; Gurley M; Okwuosa TM; Kuzel TM
Urol Oncol; 2021 Feb; 39(2):130.e9-130.e15. PubMed ID: 33132024
[TBL] [Abstract] [Full Text] [Related]
17. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy.
Ghali F; Daly WC; Hansen M; Hayn M; Sammon J; Beaule LT; Sarkar R; Murphy J; Kader AK; Derweesh I; Rose B; Ryan ST
Urol Oncol; 2021 Feb; 39(2):130.e1-130.e7. PubMed ID: 33121914
[TBL] [Abstract] [Full Text] [Related]
18. Modified J-capRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy.
Lim J; Hinotsu S; Onozawa M; Malek R; Sundram M; Teh GC; Ong TA; Thevarajah S; Zainal R; Khoo SC; Omar S; Nasuha NA; Akaza H
Cancer Med; 2020 Dec; 9(24):9346-9352. PubMed ID: 33098372
[TBL] [Abstract] [Full Text] [Related]
19. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic prostate cancer Using Disease-Specific Mortality Results From the International staging Collaboration for cancer of the prostate.
Dess RT; Suresh K; Zelefsky MJ; Freedland SJ; Mahal BA; Cooperberg MR; Davis BJ; Horwitz EM; Terris MK; Amling CL; Aronson WJ; Kane CJ; Jackson WC; Hearn JWD; Deville C; DeWeese TL; Greco S; McNutt TR; Song DY; Sun Y; Mehra R; Kaffenberger SD; Morgan TM; Nguyen PL; Feng FY; Sharma V; Tran PT; Stish BJ; Pisansky TM; Zaorsky NG; Moraes FY; Berlin A; Finelli A; Fossati N; Gandaglia G; Briganti A; Carroll PR; Karnes RJ; Kattan MW; Schipper MJ; Spratt DE
JAMA Oncol; 2020 Dec; 6(12):1912-1920. PubMed ID: 33090219
[TBL] [Abstract] [Full Text] [Related]
20. Review of the accuracy of multi-parametric MRI prostate in detecting prostate cancer within a local reporting service.
Tsai WC; Field L; Stewart S; Schultz M
J Med Imaging Radiat Oncol; 2020 Jun; 64(3):379-384. PubMed ID: 32243728
[TBL] [Abstract] [Full Text] [Related]
[Next]
